AZD6234

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Type 2 DiabetesWeight LossObesity & OverweightHepatic Impairment

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

1

Jardiance

Boehringer Ingelheim

Preclinical

312

AZD6234

AstraZeneca

Phase 2

13

Glargine

Eli Lilly

Preclinical

84

Cecon

MMcGuff Pharmaceuticals, Inc.

Preclinical

15

Nexium

DDexcel Pharma Technologies Ltd.

Preclinical

16

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

17

Sulfonylureas

Eli Lilly

Preclinical

18

SGLT-2 Inhibitor

SSheffield Teaching Hospitals NHS Foundation Trust

Preclinical

29

Henagliflozin

TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Preclinical

110

Sglt2i

UUniversity of Chicago

Preclinical

2Show 13 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Overweight4 trials

A Study in Participants With Obesity or Overweight With at Least One Weight-related Comorbidity

Completed·AstraZeneca·Phase 2·NCT06595238·262 enrolled

A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity

Recruiting·AstraZeneca·Phase 1·NCT07013643·75 enrolled

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 After Repeat Dose Administration in Participants Who Are Overweight or Obese

Active, not recruiting·AstraZeneca·Phase 1·NCT06132841·104 enrolled

Show 1 more trial

Assess the Safety, Tolerability, and Pharmacokinetics of AZD6234 Following Single Ascending Dose Administration to Healthy Subjects Who Are Overweight or Obese

Completed·AstraZeneca·Phase 1·NCT05511025·54 enrolled

Renal Impairment1 trial

Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD6234

Completed·AstraZeneca·Phase 1·NCT06845813·24 enrolled

Weight loss1 trial

A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone

Active, not recruiting·AstraZeneca·Phase 2·NCT06862791·377 enrolled

ESS1 trial

A Study to Assess the Relative Bioavailability of Different Subcutaneous Formulations ofAZD6234

Not yet recruiting·AstraZeneca·Phase 1·NCT07220954·21 enrolled

Type 2 Diabetes1 trial

Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist

Active, not recruiting·AstraZeneca·Phase 2·NCT06851858·69 enrolled

2 more indications

Hepatic Impairment1 trial

A Phase I, Multicentre, Single-Dose, Non-Randomised, Open-Label, Parallel-Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD9550 and AZD6234

Recruiting·AstraZeneca·Phase 1·NCT07546760·28 enrolled

Obesity & Overweight1 trial

A Phase IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD6234, AZD9550, and AZD6234 in Combination With AZD9550 in Chinese Participants Living With Obesity/Overweight

Active, not recruiting·AstraZeneca·Phase 2·NCT07017179·14 enrolled

Details

Drug Info

Related News